Zobrazeno 1 - 10
of 11
pro vyhledávání: '"G. J. Jesmok"'
Publikováno v:
Journal of Applied Physiology. 85:1676-1683
Ischemia-reperfusion injuries can occur with diseases such as myocardial infarction and stroke and during surgical procedures such as organ transplantation and correction of aortic aneurysms. We developed a murine model to mimic abdominal aortic aneu
Autor:
D. Douguet, Neuburger M, Norman C. Staub, G. J. Jesmok, D. Lei, C. W. Johnson, E. H. Jerome, K. Enzan
Publikováno v:
Journal of Applied Physiology. 81:1730-1738
Jerome, E. Heidi, Keiji Enzan, Dominique Douguet, Dachuan Lei, Gary Jesmok, Carol W. Johnson, Maritza Neuburger, and Norman C. Staub. Chronic interleukin-2 treatment in awake sheep causes minimal or no injury to the lung microvascular barrier. J. App
Autor:
Norman C. Staub, D. Lei, C. W. Johnson, D. Douguet, G. J. Jesmok, E. H. Jerome, D. P. Schuster
Publikováno v:
Journal of Applied Physiology. 76:909-915
Interleukin-2 (IL-2) is reputed to cause pulmonary microvascular injury. We studied the pulmonary and splanchnic microcirculation of anesthetized sheep after one dose (1.8 x 10(6) IU/kg) of IL-2 (n = 9) and after six doses (1.8 x 10(6) IU.kg-1.dose-1
Autor:
Harvey J. Sugerman, G J Jesmok, A A Fowler rd, Patrick G. Mullen, A C Windsor, C J Walsh, Bernard J. Fisher, Charles R. Blocher, Sandra K. Leeper-Woodford
Publikováno v:
The Journal of trauma. 34(5)
A number of key mediators are implicated in the pathophysiology of sepsis. In previous studies of a septic porcine model, ibuprofen pretreatment prevented the early but not the late rise in pulmonary vascular resistance index (PVRI) and the early but
Publikováno v:
Circulatory shock. 38(2)
Tumor necrosis factor alpha (TNF) has been described as a primary mediator of the pathophysiology associated with bacterial sepsis/endotoxemia. We tested the efficacy and possible mechanisms of protection of a monoclonal antibody against TNF (TNF Mab
Publikováno v:
Lymphokine and cytokine research. 10(3)
Systemic administration of recombinant human interleukin-2 (rIL-2) is used for treating some patients with advanced cancer. This therapy is limited by severe adverse reactions of cardiovascular and gastrointestinal origin. The effects of rIL-2 treatm
Publikováno v:
Surgery. 107(6)
Recombinant interleukin-2 (rIL-2) has shown promise in the treatment of patients with advanced cancer. However, toxicity of this therapy remains a major problem with its use in some patients. In this study we examined whether steroids could reduce th
Publikováno v:
Federation proceedings. 36(7)
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 200(1)
Glycerol release was employed as an index of endogenous glyceride hydrolysis in rat hearts perfused by a Langendorff technique with Krebs-Henseleit-bicarbonate buffer containing 5.5 mM glucose. Changes in cardiac contractility induced by glucagon, is